Martinez Miriam, Faiss Khristopher, Sehgal Neha
Texas Tech University Health Sciences Center at El Paso, Department of Emergency Medicine, El Paso, Texas.
Clin Pract Cases Emerg Med. 2024 Nov;8(4):326-328. doi: 10.5811/cpcem.1668. Epub 2024 Sep 29.
More than 40% of Americans are considered obese, resulting in annual healthcare costs estimated at $173 billion., Various interventions exist to address obesity including lifestyle modification, medications, and several surgical options. A novel ingestible intragastric balloon that self-deflates and is excreted approximately four months post-ingestion is being used in other countries such as Australia, Mexico, and several European countries. Currently, however, there are no US Food and Drug Administration-approved, commercially available options like this in the United States.
We present a case of a 31-year-old, obese male who presented to the emergency department for abdominal pain approximately 10 weeks after the ingestion of an inflatable balloon for weight loss treatment in Mexico. He was found to have a gastric perforation and required an emergent exploratory laparotomy.
While ingestible, weight-loss balloons are not yet commercially available in the United States, emergency physicians may still encounter complications of such devices.
超过40%的美国人被认为肥胖，导致每年的医疗保健费用估计达1730亿美元。为解决肥胖问题有多种干预措施，包括生活方式改变、药物治疗以及几种手术选择。一种新型可吞咽的胃内气球，在摄入后约四个月会自行放气并排出体外，正在澳大利亚、墨西哥和几个欧洲国家等其他国家使用。然而，目前在美国没有美国食品药品监督管理局批准的、可商业获取的此类产品。
我们报告一例31岁肥胖男性病例，该患者在墨西哥摄入用于减肥治疗的可充气气球约10周后因腹痛就诊于急诊科。他被发现有胃穿孔，需要紧急进行剖腹探查术。
虽然可吞咽的减肥气球在美国尚未商业化，但急诊医生仍可能遇到此类装置的并发症。
